Related Experiment Video
Updated: Mar 28, 2026
06:52
Behavioral and Locomotor Measurements Using an Open Field Activity Monitoring System for Skeletal Muscle Diseases
Published on: September 29, 2014
54.7K
Genome-wide expression analysis comparing hypertrophic changes in normal and dysferlinopathy mice
Yun-Sil Lee1, C Conover Talbot2, Se-Jin Lee1
1Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, 725 North Wolfe Street, PCTB 803, Baltimore, MD 21205, USA.
Genomics Data
|December 24, 2015
Summary
Blocking myostatin to promote muscle growth in dysferlinopathy mice initially improves muscle but accelerates degeneration. These findings highlight potential risks of myostatin inhibitors in muscular dystrophy.
Area of Science:
- Biochemistry
- Genetics
- Molecular Biology
Background:
- Myostatin is a key regulator of skeletal muscle mass.
- Myostatin inhibitors are being developed for muscle-wasting conditions.
- Inducing muscle hypertrophy in degenerative diseases may pose risks.
Purpose of the Study:
- To investigate the effects of myostatin inhibition on dysferlin-deficient mice.
- To analyze gene expression changes associated with hypertrophy-induced degeneration.
- To provide a data resource for understanding dysferlinopathy.
Main Methods:
- Gene expression profiling using microarrays.
- Histopathological analysis of muscle tissue.
- Bioinformatic analysis of gene expression data.
Main Results:
- Myostatin inhibition led to early histopathological improvements in dysferlin-deficient mice.
- However, myostatin inhibition ultimately accelerated muscle degeneration.
- Gene expression data revealed molecular mechanisms underlying accelerated degeneration.
Conclusions:
- Myostatin inhibition may have detrimental effects in dysferlinopathy.
- The benefits of myostatin inhibitors in muscular dystrophy require careful consideration.
- The study provides valuable data for further research into muscular degeneration.
